We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$512M 5.86%
9,050,092
+333,822
+4% +$16.6M
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$326M 3.73%
3,396,651
+99,200
+3% +$9.58M
MRNA icon
3
Moderna
MRNA
$24.5B
$308M 3.53%
2,946,913
-395,037
-12% -$40M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$293M 3.35%
1,238,985
+278,385
+29% +$63.9M
ARGX icon
5
argenx
ARGX
$53.8B
$278M 3.18%
945,348
-13,668
-1% -$3.76M
INCY icon
6
Incyte
INCY
$23.4B
$262M 3%
3,008,700
-270,750
-8% -$23.4M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$218M 2.49%
1,393,028
-28,100
-2% -$3.61M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$35.7B
$208M 2.39%
1,603,500
+43,695
+3% +$5.83M
FATE icon
9
Fate Therapeutics
FATE
$324M
$192M 2.19%
2,107,500
-110,000
-5% -$6.83M
ARVN icon
10
Arvinas
ARVN
$517M
$186M 2.13%
2,191,503
+550,000
+34% +$19M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$182M 2.08%
4,201,002
+50,000
+1% +$1.98M
HALO icon
12
Halozyme
HALO
$9.23B
$173M 1.98%
4,045,000
-1,424,131
-26% -$51.2M
ISRG icon
13
Intuitive Surgical
ISRG
$122B
$160M 1.84%
588,060
+128,508
+28% +$31.9M
ABT icon
14
Abbott
ABT
$175B
$153M 1.75%
1,396,873
+108,588
+8% +$11.8M
CRSP icon
15
CRISPR Therapeutics
CRSP
$4.71B
$139M 1.6%
909,684
-39,578
-4% -$4.68M
BIIB icon
16
Biogen
BIIB
$30.4B
$138M 1.58%
564,000
+555,400
+6,458% +$143M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$136M 1.55%
1,567,504
-12,000
-0.8% -$884K
MGNX icon
18
MacroGenics
MGNX
$285M
$135M 1.55%
5,904,517
+622,329
+12% +$14.3M
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
$135M 1.54%
7,531,414
+100,000
+1% +$1.5M
ESPR
20
DELISTED
Esperion Therapeutics
ESPR
$134M 1.53%
5,138,451
-327,264
-6% -$9.8M
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
$133M 1.52%
4,804,039
-287,961
-6% -$5.61M
DHR icon
22
Danaher
DHR
$144B
$119M 1.36%
602,120
+90,703
+18% +$18.2M
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$116M 1.33%
3,659,919
+80,000
+2% +$2.1M
BMY icon
24
Bristol-Myers Squibb
BMY
$124B
$112M 1.28%
1,804,472
+158,560
+10% +$9.75M
SRRK icon
25
Scholar Rock
SRRK
$6.33B
$111M 1.27%
2,286,651
-555,864
-20% -$20.2M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.